Professor, Deputy Director for Science, Head of the Department of Children Eye Pathology; Helmholtz National Medical Research Centre of Eye Diseases, 14/19 Sadovaya-Chernogryazskaya St., Moscow, 105062, Russia.
Researcher, Department of Children Eye Pathology; Helmholtz National Medical Research Centre of Eye Diseases, 14/19 Sadovaya-Chernogryazskaya St., Moscow, 105062, Russia.
Sovrem Tekhnologii Med. 2021;13(3):41-44. doi: 10.17691/stm2021.13.3.05. Epub 2021 Jun 28.
was to study a systemic level of L-DOPA, dopamine, and norepinephrine, and assess their prognostic value in retinopathy of prematurity (ROP) development on an experimental disease model.
The investigation was carried out on infant Wistar rats (n=36) divided into a study group (rat infants with experimental ROP, n=17) and a control group (n=19). The animals of both groups were sacrificed on days 14, 21-23, and on days 28-30. The choice of the indicated periods corresponded to the key stages of ROP development in an experiment and was based on the findings of our previous histological studies. Dopamine, L-DOPA, and norepinephrine levels in infant rat blood plasma samples were determined.
On day 14 of the experiment (the period corresponds to the pathological neovascularization induction in the applied model and preclinical ROP in children), mean L-DOPA level in infant rats with ROP (0.31 ng/ml) was significantly decreased compared to that in the controls (0.42 ng/ml) (p≤0.01). On days 21-23 of the experiment (the period corresponds to the growth of pathological extraretinal neovascularization in the applied model and ROP stage 3 in children) the systemic level of L-DOPA was still statistically reduced in the study group (0.87 ng/ml) compared to the control group (1.53 ng/ml) (p≤0.01). On days 28-30 of the experiment (the period corresponds to the regress of neovasculature in the applied model and a spontaneous ROP regress stage in children) the L-DOPA level in blood plasma in the study group (0.33 ng/ml) showed an insignificant upward tendency in reference to the controls (0.21 ng/ml). Mean dopamine and norepinephrine levels had no difference in the groups under study of infant rats within all follow-up periods.
Low systemic level of L-DOPA at the preclinical stage of experimental ROP should be considered as a laboratory prognostic criterion of a developing pathological process; it will enable to use the criterion when working out the measures to optimize the existing screening system for the disease in children.
研究左旋多巴、多巴胺和去甲肾上腺素的系统水平，并评估其在实验性疾病模型中对早产儿视网膜病变（ROP）发展的预后价值。
本研究对 36 只 Wistar 幼鼠进行了分组，分为实验组（17 只患有实验性 ROP 的幼鼠）和对照组（19 只）。两组幼鼠均在第 14、21-23 天和第 28-30 天处死。选择这些时间点对应于实验中 ROP 发展的关键阶段，并且基于我们之前的组织学研究结果。检测幼鼠血液血浆样本中多巴胺、左旋多巴和去甲肾上腺素的水平。
在实验的第 14 天（该时间点对应于应用模型中的病理性新生血管诱导和儿童的临床前 ROP），患有 ROP 的幼鼠的左旋多巴平均水平（0.31ng/ml）明显低于对照组（0.42ng/ml）（p≤0.01）。在实验的第 21-23 天（该时间点对应于应用模型中病理性视网膜外新生血管的生长和儿童的 ROP 第 3 期），实验组的左旋多巴系统水平仍明显低于对照组（0.87ng/ml）（p≤0.01）。在实验的第 28-30 天（该时间点对应于应用模型中新生血管的消退和儿童自发 ROP 消退期），实验组血液血浆中的左旋多巴水平（0.33ng/ml）与对照组（0.21ng/ml）相比呈上升趋势，但无统计学意义。在所有随访期内，实验组和对照组的幼鼠多巴胺和去甲肾上腺素的平均水平无差异。
在实验性 ROP 的临床前阶段，全身左旋多巴水平低应被视为一种正在进行的病理性过程的实验室预后标准；这将使我们能够在制定疾病的现有筛查系统的优化措施时使用该标准。
